c-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis

Shalini Tayal, Elizabeth Classen, Lynne Bemis, William A. Robinson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: c-kit expression by immunohistochemistry has been utilized to identify cancer patients who can be treated with imatinib-mesylate. In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored. Materials and Methods: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS). Immunohistochemical staining for c-kit was performed using a polyclonal antibody. Using PCR, exons 9, 10-11, 12-13 and 17 of c-kit were amplified and direct DNA sequencing performed. Results: Two out of 7 (30%) DDLS showed focal weak immunoreactivity with c-kit; no (0%) WDLS stained with c-kit. Seven out of 7 (100%) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A>C) at codon 541; 3/7 (43%) WDLS showed the same change. Conclusion: c-kit immunoreactivity did not correlate with the change in DNA sequence; DDLS showed a consistent allelic variation in c-kit that may have significant prognostic, diagnostic and therapeutic implications.

Original languageEnglish (US)
Pages (from-to)2215-2220
Number of pages6
JournalAnticancer Research
Volume25
Issue number3 B
StatePublished - May 1 2005

Fingerprint

Liposarcoma
Immunohistochemistry
Exons
Gastrointestinal Stromal Tumors
DNA Sequence Analysis
Codon
Base Pairing
Neoplasms
Staining and Labeling
Polymerase Chain Reaction
Mutation
Antibodies
Therapeutics

Keywords

  • Dedifferentiated liposarcomas
  • GISTs
  • Imatinib-mesylate
  • Polymorphism
  • Well-differentiated liposarcomas
  • c-kit

Cite this

c-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis. / Tayal, Shalini; Classen, Elizabeth; Bemis, Lynne; Robinson, William A.

In: Anticancer Research, Vol. 25, No. 3 B, 01.05.2005, p. 2215-2220.

Research output: Contribution to journalArticle

Tayal, Shalini ; Classen, Elizabeth ; Bemis, Lynne ; Robinson, William A. / c-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis. In: Anticancer Research. 2005 ; Vol. 25, No. 3 B. pp. 2215-2220.
@article{b34c62f13562416eaffe5d2cd3b8cd90,
title = "c-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis",
abstract = "Background: c-kit expression by immunohistochemistry has been utilized to identify cancer patients who can be treated with imatinib-mesylate. In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored. Materials and Methods: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS). Immunohistochemical staining for c-kit was performed using a polyclonal antibody. Using PCR, exons 9, 10-11, 12-13 and 17 of c-kit were amplified and direct DNA sequencing performed. Results: Two out of 7 (30{\%}) DDLS showed focal weak immunoreactivity with c-kit; no (0{\%}) WDLS stained with c-kit. Seven out of 7 (100{\%}) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A>C) at codon 541; 3/7 (43{\%}) WDLS showed the same change. Conclusion: c-kit immunoreactivity did not correlate with the change in DNA sequence; DDLS showed a consistent allelic variation in c-kit that may have significant prognostic, diagnostic and therapeutic implications.",
keywords = "Dedifferentiated liposarcomas, GISTs, Imatinib-mesylate, Polymorphism, Well-differentiated liposarcomas, c-kit",
author = "Shalini Tayal and Elizabeth Classen and Lynne Bemis and Robinson, {William A.}",
year = "2005",
month = "5",
day = "1",
language = "English (US)",
volume = "25",
pages = "2215--2220",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - c-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis

AU - Tayal, Shalini

AU - Classen, Elizabeth

AU - Bemis, Lynne

AU - Robinson, William A.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background: c-kit expression by immunohistochemistry has been utilized to identify cancer patients who can be treated with imatinib-mesylate. In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored. Materials and Methods: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS). Immunohistochemical staining for c-kit was performed using a polyclonal antibody. Using PCR, exons 9, 10-11, 12-13 and 17 of c-kit were amplified and direct DNA sequencing performed. Results: Two out of 7 (30%) DDLS showed focal weak immunoreactivity with c-kit; no (0%) WDLS stained with c-kit. Seven out of 7 (100%) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A>C) at codon 541; 3/7 (43%) WDLS showed the same change. Conclusion: c-kit immunoreactivity did not correlate with the change in DNA sequence; DDLS showed a consistent allelic variation in c-kit that may have significant prognostic, diagnostic and therapeutic implications.

AB - Background: c-kit expression by immunohistochemistry has been utilized to identify cancer patients who can be treated with imatinib-mesylate. In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored. Materials and Methods: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS). Immunohistochemical staining for c-kit was performed using a polyclonal antibody. Using PCR, exons 9, 10-11, 12-13 and 17 of c-kit were amplified and direct DNA sequencing performed. Results: Two out of 7 (30%) DDLS showed focal weak immunoreactivity with c-kit; no (0%) WDLS stained with c-kit. Seven out of 7 (100%) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A>C) at codon 541; 3/7 (43%) WDLS showed the same change. Conclusion: c-kit immunoreactivity did not correlate with the change in DNA sequence; DDLS showed a consistent allelic variation in c-kit that may have significant prognostic, diagnostic and therapeutic implications.

KW - Dedifferentiated liposarcomas

KW - GISTs

KW - Imatinib-mesylate

KW - Polymorphism

KW - Well-differentiated liposarcomas

KW - c-kit

UR - http://www.scopus.com/inward/record.url?scp=21344462349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344462349&partnerID=8YFLogxK

M3 - Article

C2 - 16158966

AN - SCOPUS:21344462349

VL - 25

SP - 2215

EP - 2220

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -